ACT-128800 in Psoriasis

Status:
Completed

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.

Phase 2

Actelion

Ponesimod